EUVIMEDEUVIMED entdecken
Crossref

Transcriptomic profiling and drug repurposing identify fostamatinib as a candidate therapeutic agent for IgG4-related sialadenitis

Motohisa Yamamoto iD, Ryuta Kamekura iD, Masaaki Uehara iD, Yuta Ichii iD, Kenichi Takano iD

Modern Rheumatology · 13.07.2026

DOI: 10.1093/mr/roag059 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Rheumatology, online erschienen am 13.07.2026. Verfasst von Motohisa Yamamoto und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Allergy and Clinical Immunology, IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. Die Arbeit nennt 46 Literaturangaben. Gefördert von: Takeda Science Foundation, Ministry of Health, Labour and Welfare Research Program on Rare and Intractable Diseases, JSPS KAKENHI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To identify therapeutic candidates for Immunoglobulin (Ig)G4-related sialadenitis, a manifestation of IgG4-related disease characterized by IgG4-positive plasma cell infiltration and limited treatment options beyond glucocorticoids, using transcriptomic profiling and in silico drug repurposing.

Methods

Submandibular gland tissues from 49 patients with IgG4-related sialadenitis and 3 controls were analysed by RNA sequencing. Differentially expressed genes were screened against DrugBank to identify druggable targets. Candidate drugs were prioritized based on their ability to modulate disease-associated gene signatures. Molecular docking was performed to evaluate binding affinities to key targets.

Results

Transcriptomic analysis revealed upregulation of immune-related pathways. DrugBank integration identified fostamatinib as a top candidate targeting multiple kinases, including spleen tyrosine kinase (SYK), Bruton’s tyrosine kinase (BTK), and Janus kinase 3. Docking analysis demonstrated favourable binding affinity, particularly to BTK.

Conclusions

This integrative approach highlights fostamatinib as a promising therapeutic candidate and supports a role for the SYK–BTK axis in IgG4-RD pathogenesis, suggesting a potential alternative to glucocorticoids.

Schlagwörter

Stichwörter der Autor:innen

spleen tyrosine kinaseBruton’s tyrosine kinaseIgG4-related diseaseJanus kinasefostamatinib

Autor:innen und Institutionen

  • Department of Rheumatology, Allergy and Clinical Immunology, IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Department of Otolaryngology-Head and Neck Surgery, Sapporo Medical University School of Medicine, Hokkaido, Japan.
  • Division of Cancer Cell Biology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

ORCID-Profile: Motohisa Yamamoto, Ryuta Kamekura, Masaaki Uehara, Yuta Ichii, Kenichi Takano

Förderung

  • Takeda Science Foundation
  • Ministry of Health, Labour and Welfare Research Program on Rare and Intractable Diseases
  • JSPS KAKENHI

Zitieren

APA

Yamamoto, M., Kamekura, R., Uehara, M., Ichii, Y., & Takano, K. (2026). Transcriptomic profiling and drug repurposing identify fostamatinib as a candidate therapeutic agent for IgG4-related sialadenitis. Modern Rheumatology. https://doi.org/10.1093/mr/roag059

Vancouver

Yamamoto M, Kamekura R, Uehara M, Ichii Y, Takano K. Transcriptomic profiling and drug repurposing identify fostamatinib as a candidate therapeutic agent for IgG4-related sialadenitis. Modern Rheumatology. 2026. doi:10.1093/mr/roag059

BibTeX
@article{Yamamoto2026,
  author = {Yamamoto, Motohisa and Kamekura, Ryuta and Uehara, Masaaki and Ichii, Yuta and Takano, Kenichi},
  title = {Transcriptomic profiling and drug repurposing identify fostamatinib as a candidate therapeutic agent for IgG4-related sialadenitis},
  journal = {Modern Rheumatology},
  year = {2026},
  doi = {10.1093/mr/roag059}
}
Kostenlos starten →